- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Dexcom received oversight from the FDA regarding the approval of its systems on August 19, 2025.
3 reports, 3 independent
Updated Aug 19
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dexcom received oversight from the FDA regarding the approval of its systems on August 19, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Dexcom gained FDA oversight for its systems.1 source
Potential FDA approval is expected to boost DexCom's growth.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Dexcom
company that develops, manufactures and distributes continuous glucose monitoring systems
Related events
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- Business WireSynchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D Medical device leaders who have built and scaled category-defining products join Synchron
- BarchartDexCom Stock: Analyst Estimates & Ratings DexCom, Inc. (DXCM), headquartered in San Diego, California, is a global leader in the development and manufacturing of continuous glucose monitoring (CGM) s
- ZacksWill DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? DexCom, Inc. DXCM is scheduled to release second-quarter 2025 results on July 30, after the closing bell. In the last reported qu